Why the study?
Does reaching and maintaining mitotane concentrations ≥ 14 mg/l improve recurrence-free survival in patients with radically resected adrenocortical carcinoma treated adjuvantly?
Does reaching and maintaining mitotane concentrations ≥ 14 mg/l improve recurrence-free survival in patients with radically resected adrenocortical carcinoma treated adjuvantly?
Answers are grounded in this paper and cite their sources.
Maintaining mitotane concentrations ≥ 14 mg/l during adjuvant treatment of radically resected adrenocortical carcinoma is associated with prolonged recurrence-free survival.
CONTEXT: Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC). A correlation between mitotane concentrations and patient outcome has not been demonstrated in an adjuvant setting. OBJECTIVE: To compare recurrence-free survival (RFS) in patients who reached and maintained mitotane concentrations ≥ 1 4 mg/l vs patients who did not. DESIGN AND SETTING: Retrospective analysis at six referral European centers. PATIENTS: Patients with ACC who were radically resected between 1995 and 2009 and were treated adjuvantly with mitotane targeting concentrations of 14-20 mg/l. MAIN OUTCOME MEASURES: RFS (primary) and overall survival (secondary). RESULTS: Of the 122 patients included, 63 patients (52%) reached and maintained during a median follow-up of 36 months the target mitotane concentrations (group 1) and 59 patients (48%) did not (group 2). ACC recurrence was observed in 22 patients of group 1 (35%) and 36 patients in group 2 (61%). In multivariable analysis, the maintenance of target mitotane concentrations was associated with a significantly prolonged RFS (hazard ratio (HR) of recurrence: 0.418, 0.22-0.79; P=0.007), while the risk of death was not significantly altered (HR: 0.59, 0.26-1.34; P=0.20). Grades 3-4 toxicity was observed in 11 patients (9%) and was managed with temporary mitotane discontinuation. None of the patients discontinued mitotane definitively for toxicity. CONCLUSIONS: Mitotane concentrations ≥ 14 mg/l predict response to adjuvant treatment being associated with a prolonged RFS. A monitored adjuvant mitotane treatment may benefit patients after radical removal of ACC.
No takes yet. Share an insight, caveat, or question.
Terzolo et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: